Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo

HM41322 is a novel oral sodium-glucose cotransporter (SGLT) 1/2 dual inhibitor. In this study, the in vitro and in vivo pharmacokinetic and pharmacologic profiles of HM41322 were compared to those of dapagliflozin. HM41322 showed a 10-fold selectivity for SGLT2 over SGLT1. HM41322 showed an inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyu Hang, Lee, Sang Don, Kim, Namdu, Suh, Kwee Hyun, Kim, Young Hoon, Sim, Sang Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Physiological Society and The Korean Society of Pharmacology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315097/
https://www.ncbi.nlm.nih.gov/pubmed/30627010
http://dx.doi.org/10.4196/kjpp.2019.23.1.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315097/
https://www.ncbi.nlm.nih.gov/pubmed/30627010
http://dx.doi.org/10.4196/kjpp.2019.23.1.55

Ejemplares similares